FI4045038T3 - 4-kloori-n-[2-[(4-kloorifenyyli)metyyli]-3-okso-1,2,4-tiadiatsol-5-yl]bentsamidin uudet formulaatiot - Google Patents
4-kloori-n-[2-[(4-kloorifenyyli)metyyli]-3-okso-1,2,4-tiadiatsol-5-yl]bentsamidin uudet formulaatiot Download PDFInfo
- Publication number
- FI4045038T3 FI4045038T3 FIEP20799795.8T FI20799795T FI4045038T3 FI 4045038 T3 FI4045038 T3 FI 4045038T3 FI 20799795 T FI20799795 T FI 20799795T FI 4045038 T3 FI4045038 T3 FI 4045038T3
- Authority
- FI
- Finland
- Prior art keywords
- salt
- methyl
- pharmaceutical formulation
- thiadiazol
- chlorophenyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 7
- WEDWLYRQKUTOAX-UHFFFAOYSA-N 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=CC(Cl)=CC=2)S1 WEDWLYRQKUTOAX-UHFFFAOYSA-N 0.000 title claims 3
- 150000003839 salts Chemical class 0.000 claims 18
- -1 Alkali metal salt Chemical class 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000002245 particle Substances 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 239000002775 capsule Substances 0.000 claims 7
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 6
- 239000002702 enteric coating Substances 0.000 claims 6
- 238000009505 enteric coating Methods 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 239000000945 filler Substances 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 3
- 239000004926 polymethyl methacrylate Substances 0.000 claims 3
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000009837 dry grinding Methods 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- 238000000227 grinding Methods 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 239000002952 polymeric resin Substances 0.000 claims 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 claims 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 1
- 229920003081 Povidone K 30 Polymers 0.000 claims 1
- 229920001800 Shellac Polymers 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 239000003463 adsorbent Substances 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 229920013820 alkyl cellulose Polymers 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000013871 bee wax Nutrition 0.000 claims 1
- 239000012166 beeswax Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 229940018602 docusate Drugs 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 238000010902 jet-milling Methods 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 125000000007 metacrylic acid group Chemical group 0.000 claims 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920002401 polyacrylamide Polymers 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000003340 retarding agent Substances 0.000 claims 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
- 239000004208 shellac Substances 0.000 claims 1
- 235000013874 shellac Nutrition 0.000 claims 1
- 229940113147 shellac Drugs 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- AOQGBYRBAGKHDC-UHFFFAOYSA-M sodium benzoylazanide Chemical compound [Na+].[NH-]C(=O)c1ccccc1 AOQGBYRBAGKHDC-UHFFFAOYSA-M 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 229920003002 synthetic resin Polymers 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201915094A GB201915094D0 (en) | 2019-10-18 | 2019-10-18 | New formulations |
| PCT/GB2020/052618 WO2021074646A1 (en) | 2019-10-18 | 2020-10-16 | New formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4045038T3 true FI4045038T3 (fi) | 2024-03-13 |
Family
ID=68728312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20799795.8T FI4045038T3 (fi) | 2019-10-18 | 2020-10-16 | 4-kloori-n-[2-[(4-kloorifenyyli)metyyli]-3-okso-1,2,4-tiadiatsol-5-yl]bentsamidin uudet formulaatiot |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230096218A1 (enExample) |
| EP (2) | EP4045038B1 (enExample) |
| JP (3) | JP7554263B2 (enExample) |
| KR (1) | KR20220084379A (enExample) |
| CN (2) | CN119112886A (enExample) |
| AU (1) | AU2020366142A1 (enExample) |
| CA (1) | CA3154915A1 (enExample) |
| DK (1) | DK4045038T3 (enExample) |
| ES (1) | ES2977279T3 (enExample) |
| FI (1) | FI4045038T3 (enExample) |
| GB (1) | GB201915094D0 (enExample) |
| HU (1) | HUE066075T2 (enExample) |
| MX (2) | MX2022004615A (enExample) |
| PL (1) | PL4045038T3 (enExample) |
| PT (1) | PT4045038T (enExample) |
| WO (1) | WO2021074646A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11691954B2 (en) | 2019-10-18 | 2023-07-04 | Betagenon Ab | Formulations |
| GB202100352D0 (en) * | 2021-01-12 | 2021-02-24 | Balticgruppen Bio Ab | New methods |
| WO2025017193A1 (en) * | 2023-07-20 | 2025-01-23 | Betagenon Ab | Methods of treating cardiomyopathy induced by metabolic inflexibility |
| WO2025017194A1 (en) * | 2023-07-20 | 2025-01-23 | Betagenon Ab | Methods for regulating blood glucose levels using a dual ampk activator and mitochondrial uncoupler |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2166328B1 (es) | 2000-05-11 | 2003-09-16 | Consejo Superior Investigacion | Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos |
| WO2006045581A1 (en) | 2004-10-21 | 2006-05-04 | Neuropharma, S.A. | The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators |
| UA94724C2 (en) * | 2005-12-08 | 2011-06-10 | Новартис Аг | Thiadiazolidinone derivatives as antidiabetic agents |
| JP5982281B2 (ja) | 2009-07-08 | 2016-08-31 | バルティック バイオ アーベー | 医薬として有用な化合物 |
| WO2013108026A1 (en) * | 2012-01-17 | 2013-07-25 | Baltic Bio Ab | Thiadiazolone derivatives useful in the treatment of diabetes |
| AU2018448511B2 (en) * | 2018-11-05 | 2025-07-03 | Betagenon Ab | Methods of treating diabetes in severe insulin-resistant diabetic subjects |
-
2019
- 2019-10-18 GB GB201915094A patent/GB201915094D0/en not_active Ceased
-
2020
- 2020-10-16 US US17/769,666 patent/US20230096218A1/en not_active Abandoned
- 2020-10-16 DK DK20799795.8T patent/DK4045038T3/da active
- 2020-10-16 WO PCT/GB2020/052618 patent/WO2021074646A1/en not_active Ceased
- 2020-10-16 JP JP2022523275A patent/JP7554263B2/ja active Active
- 2020-10-16 CN CN202411247521.7A patent/CN119112886A/zh active Pending
- 2020-10-16 FI FIEP20799795.8T patent/FI4045038T3/fi active
- 2020-10-16 ES ES20799795T patent/ES2977279T3/es active Active
- 2020-10-16 PL PL20799795.8T patent/PL4045038T3/pl unknown
- 2020-10-16 CA CA3154915A patent/CA3154915A1/en active Pending
- 2020-10-16 CN CN202080072849.3A patent/CN114630824B/zh active Active
- 2020-10-16 AU AU2020366142A patent/AU2020366142A1/en active Pending
- 2020-10-16 EP EP20799795.8A patent/EP4045038B1/en active Active
- 2020-10-16 EP EP23200594.2A patent/EP4316470B1/en active Active
- 2020-10-16 KR KR1020227016816A patent/KR20220084379A/ko active Pending
- 2020-10-16 PT PT207997958T patent/PT4045038T/pt unknown
- 2020-10-16 MX MX2022004615A patent/MX2022004615A/es unknown
- 2020-10-16 HU HUE20799795A patent/HUE066075T2/hu unknown
-
2022
- 2022-04-18 MX MX2025003950A patent/MX2025003950A/es unknown
-
2024
- 2024-09-06 JP JP2024153951A patent/JP7771316B2/ja active Active
-
2025
- 2025-11-05 JP JP2025186783A patent/JP2026027357A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3154915A1 (en) | 2021-04-22 |
| US20230096218A1 (en) | 2023-03-30 |
| HUE066075T2 (hu) | 2024-07-28 |
| EP4316470B1 (en) | 2026-04-29 |
| EP4045038A1 (en) | 2022-08-24 |
| JP7554263B2 (ja) | 2024-09-19 |
| CN114630824B (zh) | 2024-09-24 |
| EP4045038B1 (en) | 2023-12-06 |
| CN119112886A (zh) | 2024-12-13 |
| MX2025003950A (es) | 2025-08-01 |
| AU2020366142A1 (en) | 2022-06-02 |
| JP2022553268A (ja) | 2022-12-22 |
| PL4045038T3 (pl) | 2024-06-24 |
| WO2021074646A1 (en) | 2021-04-22 |
| MX2022004615A (es) | 2022-07-11 |
| JP2024174965A (ja) | 2024-12-17 |
| JP7771316B2 (ja) | 2025-11-17 |
| PT4045038T (pt) | 2024-03-11 |
| ES2977279T3 (es) | 2024-08-21 |
| CN114630824A (zh) | 2022-06-14 |
| GB201915094D0 (en) | 2019-12-04 |
| JP2026027357A (ja) | 2026-02-18 |
| KR20220084379A (ko) | 2022-06-21 |
| DK4045038T3 (en) | 2024-03-18 |
| EP4316470A3 (en) | 2024-02-28 |
| EP4316470A2 (en) | 2024-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4045038T3 (fi) | 4-kloori-n-[2-[(4-kloorifenyyli)metyyli]-3-okso-1,2,4-tiadiatsol-5-yl]bentsamidin uudet formulaatiot | |
| JP2022553268A5 (enExample) | ||
| ES2981985T3 (es) | Comprimidos que comprenden eltrombopag olamina | |
| ES2465478T3 (es) | Composiciones farmacéuticas que comprenden brivaracetam | |
| RU2015128609A (ru) | Перенасыщенные стабилизированные наночастицы для слаборастворимых лекарственных средств | |
| JP5416586B2 (ja) | コーティング製剤の製造方法 | |
| USRE45810E1 (en) | Process for producing spherical base granule comprising easily water-soluble drug | |
| US10172794B2 (en) | Controlled release dosage form for once daily administration of dimethyl fumarate | |
| HRP20250604T1 (hr) | Formulacije tableta neratinib maleata | |
| JP2015506377A5 (enExample) | ||
| KR20100063059A (ko) | 마이폴틱 장용정을 함유하는 서방출형 조성물 및 이의 조제방법 | |
| JP2012001460A (ja) | 光過敏性薬物の安定化法 | |
| JP2016513625A5 (enExample) | ||
| WO2012087256A2 (en) | Pharmaceutical capsule formulations | |
| JP2015063521A (ja) | 高い薬物含有率を有する錠剤及びその製造方法 | |
| CA2555295A1 (en) | Extended release coated mini-tablets of venlafaxine hydrochloride | |
| KR20080076440A (ko) | 실로스타졸의 제어방출 제제 및 그 제조방법 | |
| KR20060136409A (ko) | 벤라팍신 히드로클로라이드의 방출연장형 코팅 미니정제 | |
| JP6856326B2 (ja) | 腸放出粒子組成物 | |
| MX2013000827A (es) | Composicion de tableta de unidad multiple. | |
| WO2020006372A1 (en) | Pregabalin extended-release fomulations | |
| JP2015086194A (ja) | ラベプラゾールナトリウム含有粒子の製造方法及びそれを含む医薬組成物 | |
| KR100920856B1 (ko) | 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법 | |
| JP3718398B2 (ja) | フィルムコーティング剤及び経口固形製剤 | |
| JP7300725B2 (ja) | 固形製剤及びその製造方法 |